Name of Study: A phase I/II pharmacodynamic study of hydroxychloroquine (HCQ) in combination with gemcitabine/abraxane to inhibit autophagy in pancreatic cancer (not listed on penncancer.org currently)
Pancreatic cancer is a disease in which autophagy (digestion of cellular parts by enzymes of the same cell) plays an important role even at the earliest stages of the disease. Hydroxychloroquine is a malaria medication that can block autophagy and may, in turn, enhance cancer treatments. The goal of this trial is to evaluate how well patients respond to a new chemotherapy regimen for pancreatic cancer combined with hydroxychloroquine. Patients will receive hydroxychloroquine (HCQ) in combination with Gemcitabine and Abraxane, two chemotherapy medications.